Referências

1- YARDLEY, D. A. et al. Pooled exploratory analysis of survival in patients with HR+/HER2− advanced breast cancer and visceral metastases treated with ribociclib plus endocrine therapy in the MONALEESA trials. In: ESMO Congress 2022, Paris, França. Annals of Oncology, v. 33, supl. 7, p. S629, 2022. Poster 205P. DOI: 10.1016/j.annonc.2022.07.239. 2- LU, Y.-S. et al. Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. Clinical Cancer Research, v. 28, n. 5, p. 851–859, 1 mar. 2022. 3- HORTOBAGYI, G. N. et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. New England Journal of Medicine, v. 386, n. 10, p. 942–950, 10 mar. 2022. 4- NEVEN, P. et al. Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant. Breast Cancer Research, v. 25, n. 1, 31 ago. 2023. 5- LU, Y.-S. et al. Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. Clinical Cancer Research, v. 28, n. 5, p. 851–859, 1 mar. 2022. 6- HORTOBAGYI, G. N. et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. The New England journal of medicine, v. 375, n. 18, p. 1738–1748, 2016. 7- SLAMON, D. J. et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, v. 36, n. 24, p. 2465–2472, 20 ago. 2018. 8- BRASIL. Agência Nacional de Vigilância Sanitária (ANVISA). Bulário Eletrônico: KISQALI®️ (succinato de ribociclibe) – Bula para Profissionais de Saúde. Brasília, DF: ANVISA, [s.d.]. Disponível em: https://consultas.anvisa.gov.br/#/bulario/q/?nomeProduto=kisqali